Novartis lung cancer drug Tabrecta gets approval
Novartis receives approval from the European Commission for Tabrecta for the treatment of non-small cell lung cancer
Read More
Tag: Tabrecta
Speedy US approval for Novartis’ Tabrecta
The approval gives NSCLC patients whose tumours carry the MET exon 14 skipping mutation a new treatment option
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
